Senseonics Holdings, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $473.8M
- Price
- $9.58
- % Change (Daily % change from the live per-ticker quote feed.)
- +8.62%
- Volume
- 821.0K
About
Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the United States, Europe, the Middle East, and Africa. The company's core product offerings, Eversense and Eversense XL, are advanced implantable CGM devices. They function by continuously tracking glucose levels through an under-the-skin sensor, a detachable and rechargeable smart transmitter, and an intuitive mobile application. This setup enables real-time diabetes monitoring and management for durations of up to half a year. Senseonics delivers its products and services to healthcare providers and patients alike via an extensive network of distributors and strategic fulfillment partners. Additionally, the firm maintains a collaborative agreement with the University Hospitals Accountable Care Organization. Founded in 1996, Senseonics Holdings, Inc. is headquartered in Germantown, Maryland.
Quick stats
Shares outstanding52.9M
Computed float40.3M
Float / shares76.1%
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001616543
Websitehttps://www.senseonics.com
AI Summary
AI-generated1/23
majorbullishearnings
Senseonics Holdings, Inc. Reports Second Quarter 2026 Financial Results
Senseonics reported Q2 2026 revenue of $14.5 million, representing 120% year-over-year growth, and raised full-year revenue guidance to $62 million-$66 million.
Gross margin expanded to 59% compared to 47% in the prior year, driven by strong U.S. commercial momentum and the successful in-sourcing of European operations from Ascensia.
The company strengthened its balance sheet during the quarter with over $100 million in gross proceeds, including approximately $90 million in equity and an expanded credit facility.
Red flags
- Net loss widened to $36.7 million from $14.5 million year-over-year
- Dilutive equity offering of $90 million during the quarter